ARM vs STX

ARM exhibits strong financial health with a Piotroski F-Score of 8/9, indicating robust operational efficiency and profitability, though the absence of an Altman Z-Score prevents definitive distress risk assessment. The stock trades at a premium valuation (P/E 154.33, Forward P/E 54.10) relative to its intrinsic value estimates ($5.25 intrinsic, $11.13 Graham), suggesting high growth expectations are priced in. Despite a recent earnings decline (YoY -12.3%), revenue growth remains strong at 26.3%, supported by consistent earnings surprises in the last four quarters. However, the lack of dividend, weak technical trend, and elevated valuation pose near-term risks. Analysts remain bullish with a buy consensus and target price above current levels.

STX exhibits a stable Piotroski F-Score of 6/9, but the financial profile is characterized by extreme leverage and a significant valuation disconnect. While earnings and revenue growth are explosive (Earnings +67.7% YoY), the current price of $547.75 trades at a massive premium to its Intrinsic Value ($261.66) and Graham Number ($20.49). The stock has experienced a parabolic 1-year gain of 632%, leaving it trading above the average analyst target price of $508.47. High debt-to-equity and bearish insider activity suggest the current rally may be overextended.